Regulatory Update | CDSCO / DCC | July 2026 The Drugs Consultative Committee (DCC), at its 69th meeting, took up a proposal aimed at tightening control over one of the least regulated links in the pharmaceutical supply chain: the manufacturers…
Recent Post
- DCC intends to tighten control on manufacturing and supply of printed packaging materials used for drugs
- High-Alcohol Oral Formulations Move Into Schedule H1
- DCC Recommends Comprehensive Regulatory Mechanism to Curb Unapproved Drugs and FDCs
- DCC Recommends Mandatory Public Disclosure of Suspended and Cancelled Drug Licenses
- D&C Amended to Cover Licensing of Stem Cell Products, Gene Therapeutics and Xenografts
